In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC

Targeted Oncology

Volumn 9, Issue 3, 2014, Pages 225-237

  Nourizadeh, Maryam ^a,b   Masoumi, Farimah ^a   Memarian, Ali ^a,c   Alimoghaddam, Kamran ^d   Moazzeni, Seyed Mohammad ^e   Yaghmaie, Marjan ^d   Hadjati, Jamshid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

AML; Cytotoxic T cells; Dendritic cell; TLR agonists

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IL4 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT PROTEIN; RESIQUIMOD; TOLL LIKE RECEPTOR;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; AGONISTS; BLOOD; CELL DIFFERENTIATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; DENDRITIC CELLS; DRUG SYNERGISM; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMIDAZOLES; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; LEUKEMIA, MYELOID, ACUTE; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; POLY I-C; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 84929938717     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0285-6     Document Type: Article

References (30)

1. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368(9550):1894–1907
2. Galea-Lauri J (2002) Immunological weapons against acute myeloid leukaemia. Immunology 107(1):20–27
3. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108(2):544–550
4. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5(4):296–306
5. Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ, Frankenberger B (2010) Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 185(1):738–747. doi:10.4049/jimmunol.1000060
6. Lee JJ, Nam CE, Nam JH, Lee HC, Chung IJ, Park MS, Choi BH, Song WH, Lee IK, Park KS, Kook H, Hwang TJ, Takei M, Takaue Y, Kim HJ (2004) Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leuk Res 28(5):517–524
7. Ridgway D (2003) The first 1000 dendritic cell vaccinees. Cancer Invest 21(6):873–886
8. Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, Scholl N, Schmid C, Tischer J, Kufner S, Salih H, Kolb HJ, Schmetzer H (2010) Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother 33(2):185–199. doi:10.1097/CJI.0b013e3181b8f4ce
9. Nourizadeh M, Masoumi F, Memarian A, Alimoghaddam K, Moazzeni SM, Hadjati J (2012) Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in acute myeloid leukemia. Leuk Res. doi:10.1016/j.leukres.2012.04.007
10. Wolska A, Lech-Maranda E, Robak T (2009) Toll-like receptors and their role in hematologic malignancies. Curr Mol Med 9(3):324–335
11. Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M, Schmitt M (2008) Quantitative expression of Toll-like receptor-2, -4, and −9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion 48(5):861–870
12. Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, Nagasaki E, Kawahara H, Watanabe M, Toyama Y, Yanagisawa S, Kobayashi S, Yanaga K, Fujise K, Gong J, Tajiri H (2007) Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J Immunol 179(7):4874–4883
13. Yu L, Chen S (2008) Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 57(9):1271–1278. doi:10.1007/s00262-008-0459-8
14. Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman DM, Belyakov IM, Berzofsky JA (2008) Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A 105(42):16260–16265
15. van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27(1):49–55
16. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J (2007) Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 247(2):72–84. doi:10.1016/j.cellimm.2007.07.008
17. Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13(5):816–825. doi:10.1038/sj.cdd.4401850
18. Beck B, Dorfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ, Subklewe M (2011) Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J Transl Med 9:151. doi:10.1186/1479-5876-9-151
19. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6(8):769–776. doi:10.1038/ni1223
20. Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ (2008) Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol 181(7):5120–5127
21. Drexler HG (1987) Classification of acute myeloid leukemias—a comparison of FAB and immunophenotyping. Leukemia 1(10):697–705
22. Kohler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, Ehninger G, Bornhauser M (2000) Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 18(2):139–147. doi:10.1634/stemcells.18-2-139
23. Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L, Rajnavolgyi E (2007) Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. Blood 109(2):643–652. doi:10.1182/blood-2006-04-016840
24. Danilov SM, Sadovnikova E, Scharenborg N, Balyasnikova IV, Svinareva DA, Semikina EL, Parovichnikova EN, Savchenko VG, Adema GJ (2003) Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 31(12):1301–1309
25. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F (2002) Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51(6):299–310
26. Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H (2010) The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother 33(5):523–537. doi:10.1097/CJI.0b013e3181d87ffd
27. Santiago-Schwarz F, Coppock DL, Hindenburg AA, Kern J (1994) Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood 84(9):3054–3062
28. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA (2003) Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia. Leukemia 17(8):1683–1684, Author reply, 1684; discussion, 1685
29. Re F, Arpinati M, Testoni N, Ricci P, Terragna C, Preda P, Ruggeri D, Senese B, Chirumbolo G, Martelli V, Urbini B, Baccarani M, Tura S, Rondelli D (2002) Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Exp Hematol 30(2):126–134
30. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P (2004) Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64(17):5934–5937. doi:10.1158/0008-5472.CAN-04-1261